Abstract
Angiotensin-(1-9), a component of the non-canonical renin-angiotensin system, has a short half-life in blood. This peptide has shown to prevent and/or attenuate hypertension and cardiovascular remodeling. A controlled release of angiotensin-(1-9) is needed for its delivery to the heart. Our aim was to develop a drug delivery system for angiotensin-(1-9). Thermosensitive liposomes (LipoTherm) were prepared with gold nanoclusters (LipoTherm-AuNC) to increase the stability and reach a temporal and spatial control of angiotensin-(1-9) release. Encapsulation efficiencies of nearly 50% were achieved in LipoTherm, reaching a total angiotensin-(1-9) loading of around 180 μM. This angiotensin-(1–9)-loaded LipoTherm sized around 100 nm and exhibited a phase transition temperature of 43 °C. AuNC were grown on LipoTherm and the new hybrid nanosystem showed energy absorption in the near-infrared (NIR) wavelength range. By NIR laser irradiation, a controlled release of angiotensin-(1-9) was achieved from the LipoTherm-AuNC nanosystem. These nanosystems did not show any cytotoxic effect on cultured cardiomyocytes. Biological activity of angiotensin-(1-9) released from the LipoTherm-AuNC-based nanosystem was confirmed using an ex vivo Langendorff heart model.
Original language | English |
---|---|
Pages (from-to) | 859-872 |
Number of pages | 14 |
Journal | Journal of Controlled Release |
Volume | 328 |
DOIs | |
Publication status | Published - Dec 10 2020 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier B.V.
Funding
The authors received funding from Agencia Nacional de Investigación y Desarrollo (ANID), Chile: grants FONDAP 15130011 (to M.P.O., J.A.R., M.C., M.K. and S.L); Puente Pontificia Universidad Católica de Chile (033/2020 to M.P.O.), Fondecyt 1190623 (E.A) and 1200490 (to S.L.), Bayer AG (Program Grants4Targets ID 2017-08-2260 (to M.P.O., M.C. and S.L.), Anillo ACT192144 (to M.P.O., E.A, and J.M.), Fondecyt Postdoctoral Fellowship 3160323 (J.B) and FONDEQUIP EQM160157 and EQM170111. The authors received funding from Agencia Nacional de Investigaci?n y Desarrollo (ANID), Chile: grants FONDAP 15130011 (to M.P.O. J.A.R. M.C. M.K. and S.L); Puente Pontificia Universidad Cat?lica de Chile (033/2020 to M.P.O.), Fondecyt 1190623 (E.A) and 1200490 (to S.L.), Bayer AG (Program Grants4Targets ID 2017-08-2260 (to M.P.O. M.C. and S.L.), Anillo ACT192144 (to M.P.O. E.A, and J.M.), Fondecyt Postdoctoral Fellowship 3160323 (J.B) and FONDEQUIP EQM160157 and EQM170111.
Funders | Funder number |
---|---|
Agencia Nacional de Investigaci?n y Desarrollo | |
Agencia Nacional de Investigación y Desarrollo | FONDAP 15130011 |
FONDEQUIP | EQM160157, EQM170111 |
Puente Pontificia Universidad Cat?lica de Chile | |
Bayer | 2017-08-2260, 3160323, ACT192144 |
Fondo Nacional de Desarrollo Científico y Tecnológico | 1200490, 1190623 |
Pontificia Universidad Católica de Chile | 033/2020 |
ASJC Scopus Subject Areas
- Pharmaceutical Science